Results 1 to 10 of about 430 (81)

Estetrol‐based combined oral contraceptives: A systematic review of clinical outcomes

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 6, Page 983-998, June 2026.
This systematic review summarizes clinical outcomes of estetrol‐containing combined oral contraceptives, showing reliable contraceptive efficacy, predictable bleeding patterns, improved well‐being, and a favorable hemostatic and metabolic profile, suggesting a promising and potentially safer alternative to ethinylestradiol‐based formulations.
Mathilde Råberg, Ingeborg Rose Vad, Kara Hildur Axelsdóttir, Ellen Christine Leth Løkkegaard   +3 more
wiley   +2 more sources

Post Hoc Analysis of a Previous Study of Estetrol 15 mg/Drospirenone 3 mg Combination for Dysmenorrhea and Uterine Bleeding in Adenomyosis Patients [PDF]

Reproductive Medicine and Biology, Volume 25, Issue 1, January/December 2026.
ABSTRACT Purpose To clarify the efficacy and safety of the estetrol 15 mg/drospirenone 3 mg combination among Japanese women with adenomyosis by post hoc analyses of a previous randomized clinical study. Methods Post hoc analyses were performed using data from a 16‐week, multi‐center, randomized, double‐blinded, placebo‐controlled, parallel‐group study,
Tasuku Harada, Takao Kobayashi, Eri Koga, Masayoshi Nogami, Ayaka Sasahara, Toshiaki Takayanagi, Masashi Hirayama, Yutaka Osuga   +7 more
wiley   +2 more sources

A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 4, Page 568-574, April 2026.
It is expected that the relugolix estetrol combination RE4W will enable women to control their fertility and prevent menstrual cycle related problems, while offering a smooth transition through perimenopause into the postmenopause and decrease the risk of breast cancer.
Herjan J. T. Coelingh Bennink, Karolina Afors, Luis Bahamondes, Alessandra Graziottin, Deborah Bateson, Teresa Bombas, Yutaki Osuga, Santiago Palacios, Carolyn L. Westhoff, Kristina Gemzell‐Danielsson   +9 more
wiley   +2 more sources

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper

International Journal of Gynecology &Obstetrics, EarlyView.
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto, Martha Gulati, Suvarna S. Khadilkar, Angela H. E. M. Maas, Federica Frezet, Gláucia Maria Moraes de Oliveira, Andrea R. Genazzani, Hema Divakar, Athena Poppas, on behalf of the World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO)   +9 more
wiley   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source

The Combined Effect of Obesity and Contraceptive Use on Pulmonary Embolism in Adolescent Females Residing in the United States

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background Combined oral contraceptive (COC) use in obese adult women dramatically increases the relative risk of developing a pulmonary embolism (PE). The risk of a PE in obese adolescent females taking contraceptives is currently unknown. The purpose of this investigation was to determine the effect of body mass index (BMI) and contraceptive
John Puetz, Joanne Salas
wiley   +1 more source

Genetic ALS—Progressive Sleep Defects Precede the Onset of Clinical Disease

European Journal of Neurology, Volume 33, Issue 9, September 2026.
Sleep disturbances in people carrying ALS‐causing gene mutations progressively worsen years before motor symptoms appear. These sleep abnormalities appear to progress regardless of how close individuals are to developing clinical ALS. Thus, polysomnography‐derived sleep measures could serve as sensitive, noninvasive biomarkers for tracking preclinical ...
Christina Lang, Simon J. Guillot, Antje Knehr, Patrick Weydt, Johannes Dorst, Hayrettin Tumani, Albert C. Ludolph, Luc Dupuis, Matei Bolborea   +8 more
wiley   +1 more source

The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies

American Journal of Reproductive Immunology, Volume 96, Issue 1, July 2026.
ABSTRACT Sex hormones and reproductive transitions profoundly shape immune, metabolic, neuropsychological, and mucosal biology, as well as HIV persistence, across women's lives. Although women constitute the majority of people with HIV worldwide, hormonal and reproductive biology are still not sufficiently incorporated into HIV cure research. Cisgender
Elizabeth Hastie, Priya Khetan, Sarah A. LaMere, Ashley F. George, Rebecca Abelman, Kathleen Weber, Phyllis C. Tien, Judith D. Auerbach, Maile Karris, Todd Brown, Jonathan Karn, Loreen Willenberg, Dawn Averitt, Bridgette Picou, Nadia R. Roan, Eileen P. Scully, Karine Dubé, Nancie Archin, Sara Gianella   +18 more
wiley   +1 more source

Update of the EuroGuiDerm evidence‐based guideline for the treatment of acne—Short version

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1162-1172, July 2026.
The 2025 EuroGuiDerm guideline update provides evidence‐based recommendations for acne management, addressing systemic antibiotics, systemic isotretinoin, hormonal therapies including spironolactone and contraceptives, and new topical agents. Key considerations include treatment duration, safety, pregnancy‐specific guidance and minimizing antibiotic ...
Alexander Nast, Bassel H. Al Wattar, Marie Beylot Barry, Holger Brüggemann, Zrinka Bukvić Mokos, Dawn M. Caruana, Klaus Degitz, Clio Dessinioti, Brigitte Dréno, Rieke J. B. Driessen, Harald Gollnick, Merete Hædersdal, Alexander Katoulis, Severin Läuchli, Julien Lambert, Alison M. Layton, Giuseppe Micali, Falk R. Ochsendorf, Thozhukat Sathyapalan, Katarina Zak Stangeland, Simon Francis Thomsen, Daniel Töröcsik, Antonia Pennitz   +22 more
wiley   +1 more source